Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Study to Characterise Lung Function, Airway Morphometry, Pharyngometry and Inhalation Profiles From Patients With Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02058602
• Other study ID #: 117275
• Status: Completed
• Phase: Phase 1
• Start date: December 3, 2013
• Est. completion date: July 11, 2016

Study information

• Verified date: May 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Inhalation profiles will be recorded from patients with IPF as they inhale during tidal breathing, and following two sets of instructions (maximal effort and 'long, steady and deep' inhalation), across a range of airflow resistances that reflect those of typical inhalers used to deliver medication to the lungs. Mouth and throat dimensions will be measured using an acoustic reflectance Pharyngometer. Measurements of lung function will be made using conventional sprirometry, plethysmography and diffusion, whilst Low Dose High Resolution Computed Tomography (HRCT) will be used to scan the airways at two lung volumes; functional residual capacity (FRC) and total lung capacity (TLC). Data from HRCT will be used to reconstruct airway morphometry, and model inhaled particle deposition within the lung. Overall, the study allows a further understanding of the IPF patient population, using the data to assist in the development of new inhaled products for this disease. Following up the patients with additional HRCT scans at 3 and 6 months will enable the sensitivity of CT based criteria of disease progression to be compared with lung function criteria. No investigational product will be used in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: July 11, 2016
• Est. primary completion date: July 11, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Males/females aged 40 years and over, at the time of signing the informed consent.

• A female patient is eligible to participate if she is of: Non child-bearing potential, where females are post-menopausal, defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) >40 milliinternational units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) (<147 pmol/L) is confirmatory. Peri-menopausal or pre-menopausal, and have a negative pregnancy test as determined by serum or urine human chorionic gonadotropin (hCG) test, confirmed at screening, and then at each subsequent clinic visit before the CT scanning is conducted.

• BMI within the range 18 - 32 kilogram per meter^2 (kg/m^2) (inclusive).

• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

• Patients will have a diagnosis of IPF as determined by a responsible and experienced Respiratory physician and based on established criteria defined by the American Thoracic Society/European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

• Patient's lung function measurements of Forced vital capacity (FVC) and Diffusing capacity of the Lung for Carbon Monoxide (DLCO) at screening must fall within the category below to be included in this study: FVC >=40 % predicted and DLCO >=30 % predicted.

Exclusion Criteria:

• Patients with a current Idiopathic Pulmonary Fibrosis (IPF) exacerbation.

• Patients with a known underlying cause of pulmonary fibrosis.

• Patients that have both IPF and Chronic obstructive pulmonary disease (COPD) that requires therapy with more than an intermittent bronchodilator or a long acting muscarinic antagonist, or where the Forced Expiratory Volume in One Second (FEV1)/ Forced vital capacity (FVC) ratio is <0.65.

• Patients with an upper or lower respiratory tract infection within four weeks of Visit 1.

• Patients with a recognised co-existing respiratory disorder other than usual interstitial pneumonia (UIP) (e.g. significant COPD, asthma, sarcoid, lung carcinoma) that in the opinion of the investigator would confound the study outcomes.

• Patients with poorly controlled left ventricular heart failure.

• Serious or uncontrolled medical, surgical or psychiatric disease that in the opinion of the investigator would compromise patient safety or confound the study data (e.g. congestive cardiac failure [CCF], asthma, angina, neurological disease, liver dysfunction and blood dyscrasia).

• Patients found to have clinically significant anaemia until adequately treated.

• Patients that have a history of alcohol abuse.

• Patients who are currently taking Pirfenidone for IPF or who have received Pirfenidone within the previous 30 days prior to Visit 1.

• Patients with previous exposure to ionising radiation > 5 millieSievert (mSv) in the 3 years prior to enrolment (not including ionising radiation used for therapeutic or diagnostic purposes or for purposes that involve patient benefit).

• Patients who have a history of claustrophobia.

• As a result of the medical history, physical examination or screening investigations, the physician responsible considers the patient unfit for the study.

• The patient is unable or unwilling to perform study assessments and procedures correctly.

• The patient has received an investigational drug for IPF within 30 days of the start of the study.

• A requirement for long-term oxygen therapy (LTOT) as defined by the prescription of oxygen to be used for greater than or equal to 12 hours of therapy per day. Note - short burst oxygen therapy is permitted.

• Patient is kept under regulatory or judicial order in an institution.

• Patient is mentally or legally incapacitated.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis
• Respiratory Aspiration

Intervention

Other:
• Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
Patients are receiving no treatment on this study and there is no investigational product involved.

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Edegem

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	University Hospital, Antwerp

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To characterise the inhalation profiles	Inhalation profile was characterised by assessing Peak pressure Drop (kPa), Peak Inspiratory Flow Rate (L/min), Inhaled Volume (L), Inhalation time (s), Average Inhalation Flow Rate (L/min), Acceleration rate (L/min/s)	Up to 6 months
Primary	To characterise the pharyngometry	The pharyngometry characters were assessed by Distance (cm), Volume (cm^3), Average cross sectional area (cm^2).	Up to 6 months
Primary	Mouth and throat measurements from HRCT scan reconstruction	Mouth and throat measurements from HRCT scan reconstruction assessing Length (mm), Minimum cross-sectional area square millimetre(mm^2), Average cross-sectional area (mm^2), Concavity, Volume (mm^3)	Up to 6 months
Primary	Lung measurements from HRCT scan	Lung measurements from HRCT scan by assessing Volume, length, direction and diameter of each airway branch at FRC and TLC, Lobar volumes at FRC and TLC, Relative lobar growth from FRC to TLC, Total lung volume at FRC and TLC	Up to 6 months
Secondary	To explore the relationship between changes in airway morphometry determined by HRCT and measures of spirometry, diffusion and plethysmography	Lung function by spirometry (FVC, FEV1, Vmax25 and 50, PEFR and PIFR)	Up to 6 months

External Links

•   Results for study 117275 can be found on the GSK Clinical Study Register.